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a b s t r a c t
This is a report of a patient who had a previous diagnosis of rheumatoid arthritis, non-
erosive, rheumatoid factor negative, that despite the therapeutic approach presented pro-
gressive worsening of the articular and general condition. After extensive research, she 
had a diagnosis of hemochromatosis. Joint symptoms are common manifestations in 
hemochromatosis. The arthropathy of hemochromatosis may resemble inflammatory ar-
thropathy mimicking RA, particularly in the most common sites as 2nd and 3rd metacarpo-
phalangeal. Radiologically are observed decreased joint space, subchondral sclerosis, cyst 
formation and chondrocalcinosis. Treatment with disease modifying drugs for rheumatoid 
arthritis tend to worsen the clinical picture, since the liver is the major site of deposition of 
iron in hemochromatosis and these medications are known to be hepatotoxic. Phlebotomy 
treatment for hemochromatosis is apparently ineffective in reversing the articular mani-
festations, which requires the association with iron chelating drugs. Due to the apparent 
difficulty in differentiating between the two diseases, a screening profile of iron in patients 
with rheumatoid arthritis with atypical progression is necessary.
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r e s u m o
Este é um relato de uma paciente que teve diagnóstico prévio de artrite reumatoide, não 
erosiva, fator reumatoide negativo, que apesar da terapêutica instituída apresentava piora 
progressiva do quadro articular e do estado geral. Após extensa investigação, apresentou 
diagnóstico de hemocromatose. Sintomas articulares são manifestações frequentes na 
hemocromatose. A artropatia da hemocromatose pode assemelhar-se a artropatias infla-
matórias imitando a AR, particularmente nos sítios mais comuns, como 2ª e 3ª metacarpo-
falangeanas. Radiologicamente são observadas diminuição do espaço articular, esclerose 
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subcondral, formação de cistos e condrocalcinose. O tratamento com drogas modificadoras 
de doença para artrite reumatoide tende a piorar o quadro clínico, uma vez que o fígado 
é o principal sítio de depósito de ferro na hemocromatose e essas medicações são sabida-
mente hepatotóxicas. O tratamento com flebotomia para hemocromatose é aparentemente 
ineficaz na reversão das manifestações articulares, sendo necessária a associação com me-
dicações quelantes de ferro. Devido à dificuldade aparente de diferenciação entre as duas 
patologias, faz-se necessária uma triagem no perfil do ferro em pacientes com diagnóstico 
de artrite reumatoide com evolução atípica.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction 
Hemochromatosis (HC) is a disorder of iron metabolism 
characterized by increased intestinal iron absorption and 
progressive deposition in organs and tissues, resulting in in-
jury and functional impairment, particularly the liver, pan-
creas, heart, joints and pituitary.1 It affects more often males 
in the fourth and fifth decade. Schumacher, in 1964, was the 
first to recognize the relationship between HC and arthritis.2 
Although arthritis in the second and third metacarpopha-
langeal (MCP) joints is often observed as a typical finding of 
HC, virtually all joints can be affected, with signs and symp-
toms of osteoarthritis.3.4 Sometimes, it can be observed in-
termittent arthritis leading to misdiagnosis of rheumatoid 
arthritis.5
Rheumatoid arthritis (RA) is a symmetric, progressive, au-
toimmune, chronic inflammatory polyarthritis of unknown 
cause that affects about 1% of the adult population. It is most 
common in women between the fourth and sixth decades.
This paper aims to report a case of HC with a diagnosis of RA.
Case report
Female patient, 56 years old, white, married, born in Minas 
Gerais, residing in Sao Paulo, homemaking, complaining of 
joint pain in hands and knees associated with morning stiff-
ness greater than 1 h. At the physical examination, synovitis 
was observed in the right (R) and left (L) 2nd proximal inter-
phalangeal (PIP) joints and in the 2nd and 3rd MCP R and L, 
wrists, knee (R) and sternoclavicular joint (L). Radiography 
(RX) of hands, knees and feet revealed diffuse bone thinning 
with space preserved in the hands; prominent tibial spine, 
subchondral cysts, osteophytes and reduced joint space in 
knees; the laboratory analysis showed an increase of trans-
aminases – ALT: 207 (n = 7-35 U/L), AST: 127 (n = 8-33 U/L) 
and increased ESR: 41 (n = 0-10 mm), with no other changes, 
including serology. RA was suspected, and the patient was 
treated with chloroquine 250 mg/day and steroid depot at 
the time of appointment. In addition, abdominal ultrasound 
was requested, due to increase of transaminases, with nor-
mal results.
Upon returning in consultation, no significant clinical im-
provement was observed. The laboratory workup showed a 
negative rheumatoid factor, normalization of transaminases 
and reduction of ESR; AST 23, ALT, 25, VHS 21. At this time, a 
diagnosis of erosive RA with negative rheumatoid factor was 
established. Methotrexate (MTX) 15 mg/week was prescribed. 
After 6 months, the patient returns with the same clinical and 
laboratory findings. The patient presented grayish blemishes, 
bruises and small dilated vessels in the lower limbs (LL), in 
association with arthritis. We chose to increase the dose of 
MTX to 20 mg/week, with no clinical response. Because of 
skin changes and no response to treatment with DMARD and 
corticosteroid, we chose to investigate the patient profile of 
iron, with the following findings: Iron: 224 (n = 37-170 μg/dL), 
iron binding capacity: 244 (n = 250-450 μg/ dL), transferrin sat-
uration: 91.8 (n = 20-60%), ferritin: 2140 (n = 11.1-264 ng / mL), 
RBC unchanged; AST, 53; ALT, 83, ESR, 17; hemochromatosis 
was hypothesized. Magnetic resonance imaging of the liver 
with iron deposits was requested, with alteration: 250 μmcL/g 
(n = 36 μmcL/g); and the C282Y and H63D mutation in HFE 
gene survey resulted in a mutated homozygous genotype for 
C282Y and absence of H63D mutation, with confirmation of 
the diagnosis.
At this time, MTX was discontinued and the corticoste-
roid was gradually suppressed, and the patient was referred 
to the hematology service, where she is being followed and 
treated with phlebotomy sessions and an iron chelator (de-
feroxamine).
Currently, after 8 phlebotomy sessions the patient only 
shows synovitis in 2nd and 3rd PIP D and E, and intermittent 
episodes of joint pain in knees, without morning stiffness. 
Laboratory workup: Fe, 234; transferrin saturation, 57%, fer-
ritin, 975, AST 38, SGPT, 44; RBC unchanged.
Discussion
Familial hemochromatosis is the most common autosomal 
recessive hereditary disease, with a prevalence of approxi-
mately 1:400 in the European population, and is often under-
diagnosed as a cause of arthropathy. This disease is caused 
by a mutation in the HFE gene located on chromosome 6.6 
HFE protein binds to the transferrin receptor, diminishing the 
receptor affinity to FE ion, thereby interfering in its metabo-
lism.1,3 Two mutations in the HFE gene were identified: one 
resulting in the substitution of cysteine  at 282 position by ty-
rosine (C282Y), and the other resulting in the substitution of 
histidine at position 63 by aspartic acid (H63D).
It has been shown that most patients with clinical mani-
festations of HC are homozygous for C282Y mutation, as ob-
served in the case of our patient, and about 5% are C282Y/
H63D heterozygous.4,5 Recent studies have revealed that the 
prevalence of C282Y mutation in patients with RA did not dif-
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fer from the control population.7,8 Moreover, H63D mutation 
is more frequent in RA population versus healthy controls.8 
However, in contrast to C282Y mutation, H63D mutation is 
not associated with iron metabolism.2,8
Joint symptoms are common manifestations in HC (about 
30% of patients), which are sometimes reported as the first 
symptom of the disease, similar to that observed in our 
patient. Typically, 2nd and 3rd MCP are involved, but other 
joints such as wrists, knees, hips, shoulders and ankles may 
also be affected9,10. Radiologically, decreased joint space, 
subchondral sclerosis, cyst formation and chondrocalcinosis 
are observed. Treatment with phlebotomy for HC is appar-
ently ineffective in reversing the joint manifestations and, 
in some patients, progression of these symptoms with de-
creased levels of iron have been described.11 Our patient ini-
tially presented clinical improvement after the implementa-
tion of phlebotomy therapy.
The arthropathy of hemochromatosis may resemble rheu-
matoid arthritis, because one of its manifestations may be a 
symmetrical arthritis in MCP; rheumatoid factor can be posi-
tive; ferritin, a marker of iron overload, can be increased in 
other inflammatory conditions such as RA.12 Thus, diagnostic 
difficulties may arise in differentiating between RA and HC 
arthropathy, which will delay a proper treatment.
The clinical treatment of patients with HC and an early di-
agnosis of RA are difficult because 83% of the patients exhibit 
liver involvement – and the liver is one of the major sites of 
iron deposition. At the same time, many DMARDS used in the 
treatment of RA have high hepatotoxicity. Furthermore, it has 
been demonstrated that DMARDS, as MTX, can increase se-
rum iron levels.13 On the other hand, iron is known to catalyze 
oxidative reactions, with subsequent formation of hydroxyl 
radicals and lipid peroxidation, which can cause inflamma-
tion and tissue damage.
Furthermore, it has been shown that iron stimulates DNA 
synthesis in synovial cells, with an additive effect on cell pro-
liferation, together with cytokines such as IL-1 β and TNF-α. 
These findings emphasize the role of iron as a modulator 
of disease activity in RA. The hypothesis would be that the 
patient's treatment with MTX would result in an increase in 
serum iron levels, activating a latent HC and leading to the ex-
acerbation of joint manifestations.14 This was observed in our 
patient, who suffered clinical worsening of the joint picture 
after the introduction of MTX.
Due to the high prevalence of RA and HC in the general 
population, this fact reinforces the usefulness of the screen-
ing for HFE gene mutation in patients with RA with atypical 
development of the disease, as well as in patients with undif-
ferentiated arthritis.
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